At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19)
In Brief
An observational study for Androgenetic Alopecia and 5 related conditions. Completed, enrolled 300 participants across 1 site.
Detailed Summary
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAndrogenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness, Female Pattern Baldness, COVID-19 Pneumonia
CountriesPakistan
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartDec 2020
Primary CompletionMar 2021
First PostedMay 2021
TodayJul 2026
First PostedMay 24, 2021
Enrollment StartDec 1, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.1 years ago